Literature DB >> 33542062

Telemedicine medical abortion at home under 12 weeks' gestation: a prospective observational cohort study during the COVID-19 pandemic.

John Joseph Reynolds-Wright1,2, Anne Johnstone3,2, Karen McCabe3,2, Emily Evans4, Sharon Cameron3,2.   

Abstract

BACKGROUND: In response to the COVID-19 pandemic, legislation and guidance were introduced in Scotland permitting medical abortion at home by telemedicine for pregnancies at less than 12 weeks' gestation. Women had a telephone consultation with a clinician. Routine ultrasound was not performed. Medications and a low-sensitivity pregnancy test to confirm success of treatment were collected by or delivered to the woman, with telephone support provided as needed.
METHODS: A prospective cohort study of 663 women choosing medical abortion at home via the NHS Lothian telemedicine abortion service between 1 April and 9 July 2020. Interviewer-administered questionnaires were completed 4 and 14 days following treatment. Regional hospital databases were reviewed to verify abortion outcomes and complications within 6 weeks. Outcome measures included efficacy, complications and acceptability.
RESULTS: Almost all (642/663, 98.2%) the women were under 10 weeks' gestation. For 522/663 (78.7%) women, gestation was determined using last menstrual period alone. Some 650/663 (98%) women had a complete abortion, 5 (0.8%) an ongoing pregnancy and 4 (0.6%) an incomplete abortion. No one was treated inadvertently beyond 12 weeks' gestation, but one woman was never pregnant. One woman who had a pre-abortion ultrasound was later managed as a caesarean scar ectopic. There were two cases of haemorrhage and no severe infections. Some 123 (18.5%) women sought advice by telephone for a concern related to the abortion and 56 (8.4%) then attended a clinic for review. Most (628, 95%) women rated their care as very or somewhat acceptable.
CONCLUSIONS: This model of telemedicine abortion without routine ultrasound is safe, and has high efficacy and high acceptability among women. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Entities:  

Keywords:  COVID-19; abortion; health Services Research; induced; mifepristone; reproductive health; therapeutic

Year:  2021        PMID: 33542062     DOI: 10.1136/bmjsrh-2020-200976

Source DB:  PubMed          Journal:  BMJ Sex Reprod Health        ISSN: 2515-1991


  6 in total

1.  Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study.

Authors:  Ara Aiken; P A Lohr; J Lord; N Ghosh; J Starling
Journal:  BJOG       Date:  2021-03-24       Impact factor: 7.331

2.  "I just was really scared, because it's already such an uncertain time": Exploring women's abortion experiences during the COVID-19 pandemic in Canada.

Authors:  Srishti Hukku; Andréanne Ménard; Julia Kemzang; Erin Hastings; Angel M Foster
Journal:  Contraception       Date:  2022-02-03       Impact factor: 3.051

3.  Access to and quality of sexual and reproductive health services in Britain during the early stages of the COVID-19 pandemic: a qualitative interview study of patient experiences.

Authors:  Raquel Bosó Pérez; David Reid; Karen J Maxwell; Jo Gibbs; Emily Dema; Christopher Bonell; Catherine H Mercer; Pam Sonnenberg; Nigel Field; Kirstin R Mitchell
Journal:  BMJ Sex Reprod Health       Date:  2022-04-20

Review 4.  Legal and non-legal barriers to abortion in Ireland and the United Kingdom.

Authors:  Sydney Calkin; Ella Berny
Journal:  Med Access Point Care       Date:  2021-08-19

5.  Why women choose at-home abortion via teleconsultation in France: drivers of telemedicine abortion during and beyond the COVID-19 pandemic.

Authors:  Hazal Atay; Helene Perivier; Kristina Gemzell-Danielsson; Jean Guilleminot; Danielle Hassoun; Judith Hottois; Rebecca Gomperts; Emmanuelle Levrier
Journal:  BMJ Sex Reprod Health       Date:  2021-07-28

6.  Women's experiences of a telemedicine abortion service (up to 12 weeks) implemented during the coronavirus (COVID-19) pandemic: a qualitative evaluation.

Authors:  N Boydell; J J Reynolds-Wright; S T Cameron; J Harden
Journal:  BJOG       Date:  2021-07-27       Impact factor: 7.331

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.